Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the efficacy and safety of intraocular injections of bevacizumab in patients with macular edema (ME) following branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

Methods

Retrospective, non-comparative case series. Patients ≥18 years of age with ME secondary to BRVO or CRVO who received a minimum of one intravitreal injection of bevacizumab with a follow-up >3 months were included. Primary endpoints were mean change in best corrected visual acuity (BCVA) from baseline to 12 and 24 months, and mean change in central macular thickness (CMT) after 3 injections. Secondary endpoints were mean change in BCVA and CMT from baseline to end of follow-up, number of injections, and ocular adverse events.

Results

Eighty-seven eyes with BRVO and 65 eyes with CRVO were included. Mean follow-up time was 24.4 and 26.1 months in the BRVO and CRVO groups, respectively. The mean change in BCVA was 0.25 LogMAR in the BRVO group and −0.118 LogMAR in the CRVO group.

Conclusion

Visual acuity outcomes in the CRVO group were poorer, especially in patients with low baseline BCVA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732. doi:10.1001/archopht.124.5.726

    Article  PubMed  Google Scholar 

  2. The Royal College of Ophthalmologists, Interim Guidelines for Management of Retinal Vein Occlusion, December 2010. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdf. Accessed 6 May 2015

  3. Lucentis 10 mg/ml solution for injection - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/19409. Accessed 6 May 2015

  4. Eylea 40mg/ml solution for injection in a vial - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/27224. Accessed 6 May 2015

  5. Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 117:1102–1112.e1. doi:10.1016/j.ophtha.2010.02.021

    Article  PubMed  Google Scholar 

  6. Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for Macular Edema following Central Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. doi:10.1016/j.ophtha.2010.02.022

    Google Scholar 

  7. Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. doi:10.1016/j.ophtha.2011.12.005

    Article  PubMed  Google Scholar 

  8. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  9. PAT survey highlights shifting trends in practice preferences | OSN Retina. http://www.healio.com/ophthalmology/retina-vitreous/news/print/osn-retina/%7B857f9212-d7f4-4cff-b9f3-6d0f85748c8a%7D/pat-survey-highlights-shifting-trends-in-practice-preferences. Accessed 6 May 2015

  10. Epstein DL, Algvere PV, Von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591. doi:10.1016/j.ophtha.2012.06.037

    Article  PubMed  Google Scholar 

  11. Prager F, Michels S, Kriechbaum K et al (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. doi:10.1136/bjo.2008.141085

    Google Scholar 

  12. Zhang H, Liu Z-L, Sun P, Gu F (2011) Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27:615–621. doi:10.1089/jop.2011.0050

    Article  CAS  PubMed  Google Scholar 

  13. Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev CD007325. doi:10.1002/14651858.CD007325.pub2

  14. Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538. doi:10.1371/journal.pone.0078538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brown DM, Wykoff CC, Wong TP, et al. (9000) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: The Rubeosis Anti-VEGF (RAVE) Trial. Retina. doi:10.1097/IAE.0000000000000191

  16. Campochiaro PA, Brown DM, Awh CC et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049. doi:10.1016/j.ophtha.2011.02.038

    Article  PubMed  Google Scholar 

  17. Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602. doi:10.1016/j.ophtha.2011.02.022

    Article  PubMed  Google Scholar 

  18. Central T, Occlusion V, Group S, Library PM (1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486–91

  19. Hayreh SS (2014) Ocular vascular occlusive disorders: Natural history of visual outcome. Prog Retin Eye Res 41C:1–25. doi:10.1016/j.preteyeres.2014.04.001

    Article  Google Scholar 

  20. Hayreh SS, Rojas P, Podhajsky P et al (1983) Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 90:488–506

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, The Soroka University Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel

    Tom Kornhauser

  2. Tel Aviv Sourasky Medical Center and The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Roy Schwartz, Michaella Goldstein, Meira Neudorfer, Anat Loewenstein & Adiel Barak

Authors
  1. Tom Kornhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michaella Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meira Neudorfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anat Loewenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Adiel Barak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tom Kornhauser.

Additional information

Tom Kornhauser and Roy Schwartz are equal contributing first authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kornhauser, T., Schwartz, R., Goldstein, M. et al. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol 254, 835–844 (2016). https://doi.org/10.1007/s00417-015-3130-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-3130-z

Keywords

Search

Navigation